Special Issue "Resveratrol"
Deadline for manuscript submissions: closed (31 August 2014)
Dr. Paul van Ginkel
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA
Interests: cancer; angiogenesis; signal transduction pathways; drug development
Natural products are broadly defined as chemical substances made by living organisms, often associated with potentially beneficial applications. Although the use of natural products has ancient origins, their popularity should not be considered solely an historic default; in spite of ample time and effort by the worldwide pharmaceutical industry to employ high-throughput screening for the evaluation of combinatorial chemistry products, from 1981–2006 only 30% of New Chemical Entities covering all diseases were of synthetic origin, while the remaining compounds were largely natural products, their derivatives and mimics.
Of the more promising natural products under investigation, resveratrol has attracted the most attention because of its effects on cell signaling pathways relevant to disparate diseases. Resveratrol, a simple polyphenol (trans-3,5,4'-trihydroxystilbene), is found in many plants consumed in the normal diet such as grapes, berries and peanuts, as well as in other plant sources used as herbal medicines. In addition to cardioprotective and neuroprotective properties, resveratrol has been reported to provide protection against various cancers, diabetes, inflammatory diseases and senescence. Plant extracts containing resveratrol also have been reported to possess clinically relevant anti-oxidant activity.
However, it is not always clear how resveratrol causes different or even opposite effects in different cell types and in different diseases. For example, resveratrol can cause tumor cell death while it acts as an anti-apoptotic agent in nerve cells. Similarly, resveratrol is anti-angiogenic in many models of cancer yet pro-angiogenic in such maladies as myocardial infarction. Resveratrol can increase mitochondrial health in muscle cells while it induces
mitochondria-mediated apoptosis in tumor cells. It is apparent that the mechanisms of action of resveratrol need to be more fully elucidated and incorporated into larger cellular pathways to determine how it has such diverse activities in dissimilar cells and diseases. Ultimately, bona fide clinical trials also are needed to validate any claims of efficacy and to test improved formulations of resveratrol aimed at enhancing its bioavailability and expanding its modes of delivery.
To encompass the remarkable breadth of ongoing resveratrol research, articles covering a wide range of topics, including but not exclusive to metabolism, signaling pathways, pre-clinical studies, drug formulations and clinical trials are welcomed for inclusion in this Special Issue of Molecules.
Dr. Arthur S. Polans
Dr. Paul van Ginkel
Dr. Veronika Somoza
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- metabolism and bioavailability
- cellular mechanisms of action
- drug development
- pre-clinical studies
- clinical trials
- nutrition and epidemiology